Results 201 to 210 of about 8,411,708 (236)

Inhibition of a live-attenuated chlamydia oral vaccine in the large intestine is dependent on CD11c-expressing cells that produce IL-23. [PDF]

Sci Rep
He Y, Abdelsalam AM, Wu Y, Rodroguez M, Fan H, Zhong G.   +5 more
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Enhancing IgG fragment crystallizable sialylation improves the therapeutic activity of IL-23 cytokine blockade. [PDF]

JCI Insight
Kämpf S, Hematianlarki M, Altmann L, Bright JM, Toda AM, Mirzapoor Z, Zollner V, Werner A, Bulang J, Radovani B, Wöhner M, Avery W, Karbarz MJ, Conley PB, Coffey GP, Nimmerjahn F.   +15 more
europepmc   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials

Central European Journal of Immunology
Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou   +9 more
doaj   +1 more source

Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study. [PDF]

Ther Adv Musculoskelet Dis
Parisi S, Becciolini A, D'Onofrio B, Lo Gullo A, Addimanda O, Magnani M, Reta M, Andracco R, Mansueto N, Del Medico P, Caccavale R, Paroli M, Larosa M, Bianchi G, Camellino D, Raffeiner B, Nucera V, Ianniello A, Giampietro C, Ometto F, Priora M, Molica Colella AB, Bravi E, Platè I, Arrigoni E, Ravagnani V, Bezzi A, Mascella F, Focherini MC, Fiorenza A, Rovera G, Vitetta R, Scolieri P, Bruzzese V, Volpe A, Bixio R, Marchetta A, Lumetti F, Farina A, Bernardi S, Girelli F, Visalli E, Amato G, De Lucia F, Dal Bosco Y, Foti R, Foti R, Serale F, Cipollone F, Di Penta M, Sabatini E, Celletti E, Franchina V, Colella FM, Ferrero G, Sandri G, Giuggioli D, Ditto MC, Fusaro E, Adorni G, Di Donato E, Santilli D, Lucchini G, Ariani A.   +63 more
europepmc   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Neuropsychiatric Outcomes of IL-17 and IL-23 Inhibitors in Dermatology: Risks, Benefits, and Clinical Implications. [PDF]

Int J Dermatol
Tan IJ, Mitelman A, Jafferany M.
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source